Table 3. Association between physician sex and initial cholinesterase inhibitor dose prescribed.
| Groups | Physician Sex | Unadjusted | Patient adjusted* | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Lower-than-Recommended initial dose** | Higher-than- Recommended initial dose** | Lower-than-Recommended initial dose** | Higher-than- Recommended initial dose** | ||||||
| OR (95% CI) | P-value | OR (95% CI) | P-value | AOR (95% CI) | P-value | AOR (95% CI) | P-value | ||
| Overall | Male | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | ||||
| Female | 1.43 (1.17–1.74) |
0.0004 | 0.90 (0.78–1.03) |
0.1369 | 1.34 (1.08–1.65) |
0.0068 | 0.89 (0.77–1.03) |
0.1211 | |
| Family Medicine/General practice | Male | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | ||||
| Female | 1.33 (1.07–1.64) |
0.0087 | 0.91 (0.79–1.04) |
0.1775 | 1.31 (1.06–1.62) |
0.0121 | 0.93 (0.80–1.07) |
0.2847 | |
| Dementia Specialist (Geriatric Medicine, Psychiatry, Neurology) | Male | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | ||||
| Female | 3.81 (2.54–5.72) |
< .0001 | 0.76 (0.53–1.08) |
0.1198 | 3.68 (2.47–5.49) |
< .0001 | 0.78 (0.55–1.10) |
0.1572 | |
| Geriatric Medicine | Male | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | ||||
| Female | 2.84 (1.45–5.56) |
0.0023 | 1.29 (0.83–2.00) |
0.2587 | 2.76 (1.39–5.51) |
0.0039 | 1.33 (0.85–2.09) |
0.2087 | |
| Psychiatry | Male | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | ||||
| Female | 3.17 (1.58–6.37) |
0.0012 | 0.58 (0.34–0.98) |
0.0427 | 3.00 (1.48–6.08) |
0.0023 | 0.60 (0.36–0.99) |
0.0440 | |
| Neurology | Male | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | ||||
| Female | 3.27 (1.76–6.06) |
0.0002 | 1.14 (0.57–2.28) |
0.7168 | 3.25 (1.73–6.11) |
0.0003 | 1.17 (0.58–2.35) |
0.6593 | |
| Non Dementia Specialist | Male | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | ||||
| Female | 1.34 (0.74–2.45) |
0.3355 | 1.05 (0.64–1.72) |
0.8366 | 1.27 (0.69–2.34) |
0.4358 | 1.02 (0.62–1.67) |
0.9400 | |
*Adjusted for patient age (continuous), sex, income quintile, rural residence, number of ADGs (continuous), acute myocardial infarction, asthma, angina, arrhythmia, cancer, diabetes, congestive heart failure, hypertension, stroke, liver disease, renal disease, mood/anxiety disorders, and number of concurrent medications used.
** Compared to recommended initial dose
ref: reference category.